Chahoud Georges, Joseph Jacob
Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock 72205, USA.
Curr Opin Cardiol. 2003 Sep;18(5):400-5. doi: 10.1097/00001573-200309000-00013.
Chronic heart failure continues to exact a heavy burden on society due to high morbidity and mortality, in spite of advances in management. Beta-adrenergic blockade, by the suppression of sympathetic activity, attenuates the adverse ventricular remodeling seen in heart failure, and decreases mortality and hospitalization rates. Recently reported trials, meta-analyses, and sub-analyses extend the benefit of beta-blockade to severe heart failure, women, elderly patients, and African Americans. In addition, recent data also indicate the cost-effectiveness of beta-blockade in combating this deadly disease. These data indicate the strength of evidence for the use of beta-blockade for most patients with chronic heart failure.
尽管在治疗方面取得了进展，但由于发病率和死亡率居高不下，慢性心力衰竭继续给社会带来沉重负担。β-肾上腺素能阻滞剂通过抑制交感神经活动，减轻心力衰竭中出现的不良心室重塑，并降低死亡率和住院率。最近报道的试验、荟萃分析和亚组分析将β-阻滞剂的益处扩展到严重心力衰竭、女性、老年患者和非裔美国人。此外，最近的数据还表明β-阻滞剂在对抗这种致命疾病方面具有成本效益。这些数据表明了大多数慢性心力衰竭患者使用β-阻滞剂的证据强度。
